HMB Supplements to See If they Help Inflammation and Recovery After Head and Neck Cancer Surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind trial assigns adults with head and neck cancer to receive either 3 g/day of HMB or a maltodextrin placebo for 30 days before planned curative surgery. Researchers will measure nutritional status, muscle strength, and quadriceps muscle thickness, along with lab markers, to see how the supplement affects inflammation and early postoperative outcomes. Postoperative results will be tracked in medical records to evaluate recovery and complications. The goal is to determine if HMB can help patients maintain muscle and reduce surgery-related inflammation. The study is conducted at the Federal University of Minas Gerais in Belo Horizonte, Brazil.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals aged 18 years or older;
* Both sexes (male and female);
* Patients treated at the outpatient clinic for head and neck carcinoma;
* Indication for potentially curative tumor resection surgery.

Exclusion Criteria:

* Diagnosis of cancer of the face, skin, paranasal sinuses, or thyroid;
* Undergoing neoadjuvant or palliative treatment;
* Cognitive or intellectual impairment that may hinder proper understanding of the study;
* Refusal to participate or to sign the informed consent form.

Where it's running

• School of Medicine, Federal University of Minas Gerais
  Belo Horizonte, Minas Gerais, Brazil Recruiting

Study contacts

• Principal investigator: Marcus Vinícius M Andrade, MD, PhD — Department of Medicine, Federal University of Minas Gerais
• Study coordinator: Marcus Vinícius M Andrade, MD, PhD
• Email: andrademufmg@gmail.com
• Phone: +55 31 98805-3393

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cough Skill Training to Help Head and Neck Cancer Patients Recover Voluntary Cough

  Researchers will test whether a handheld cough device-based training can help people with head and neck cancer improve their voluntary cough function.

  Recruiting Boston University Charles River Campus · Boston, Massachusetts · NCT07756684

• Dietary fiber and sarcopenia risk in head and neck cancer

  This observational study will track fiber intake and related biological markers in adults with head and neck cancer from diagnosis for six months to see if higher fiber intake relates to better muscle health and lower inflammation during treatment.

  Recruiting University of Oklahoma · Oklahoma City, Oklahoma · NCT07622914

• EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma

  This phase 1 trial will try EPI-326, a new drug, in people with EGFR-mutant non‑small cell lung cancer or advanced head and neck squamous cell carcinoma to find safe doses, study how the body handles it, and look for early signs it shrinks tumors.

  Recruiting at 8 sites Phase 1 EpiBiologics · Los Angeles, California and 7 other locations · NCT07462377

• Group program to promote post-traumatic growth for adults with breast, colorectal, or head and neck cancer in Greece

  This project will try a manualized, group-based ACT program to help Greek adults who finished chemotherapy for breast, colorectal, or head and neck cancer increase post-traumatic growth and quality of life.

  Recruiting Centre for Research and Technology Hellas · Thessaloniki · NCT07108517

• Telemedicine follow-up for early laryngeal cancer patients

  This study tests if follow-up care through Telemedicine is just as good as in-person visits for people with early laryngeal cancer, especially for those who live far from treatment centers.

  Recruiting University Medical Center Groningen · Groningen, Provincie Groningen · NCT06940505

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.